Quality control and comparative study of the formulation process of two drugs: Paralgan® 500 mg and Doliprane® 500 mg
| dc.contributor.author | BENNAMANE Kenza | |
| dc.contributor.author | DHAOUI Nabila (Encadrant) | |
| dc.date.accessioned | 2025-11-18T10:08:39Z | |
| dc.date.available | 2025-11-18T10:08:39Z | |
| dc.date.issued | 2025 | |
| dc.description.abstract | The aim of this work is a comprehensive study of a generic drug Paralgan®500mg produced by the Algerian pharmaceutical group SAIDAL DAR EL BEIDA.The study covers the various stages in the manufacture of this drug resulting in a pharmaceutical product complying with international standards, and the monitoring of various techniques for validating dosing methods. The results obtained from the physico-chemical analysis of the active ingredient (Paracetamol) comply with recommended standards. A quality comparison between this generic drug and its original drug (Doliprane®500mg) manufactured by the French pharmaceutical group SANOFI clearly shows their equivalence and compliance with international standards. Analysis of accelerated and long-term stability data under various storage conditions (temperature, humidity, light) will provide a better understanding of the factors influencing product durability, and enable us to optimize storage conditions. | |
| dc.identifier.uri | http://dspace.ensti-annaba.dz:4000/handle/123456789/948 | |
| dc.language.iso | en | |
| dc.publisher | National Higher School of Technology and Engineering-Annaba | |
| dc.title | Quality control and comparative study of the formulation process of two drugs: Paralgan® 500 mg and Doliprane® 500 mg | |
| dc.type | Thesis |